Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.2.0.727
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
6 Months Ended
Jun. 30, 2015
Merck KGaA  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]  
Percentage share of eligible worldwide development expenses 70.00%